Safety issues associated with proton pump inhibitors (PPIs) have recently attracted
widespread media and lay attention. Gastroenterologists are frequently asked about the …

Thirty years ago, disorders associated with inappropriate levels of gastric acid were a major
problem for which treatment options were limited, and approaches to the control of gastric …

Synopsis Omeprazole is the first of a new class of drugs, the acid pump inhibitors, which
control gastric acid secretion at the final stage of the acid secretory pathway and thus reduce …

The extent of duodenal bacterial overgrowth during the pronounced inhibition of acid
secretion that occurs with omeprazole treatment is unknown. The bacterial content of …

Abstract Background/Aims: Patients with reflux esophagitis have rapid relapses after
treatment withdrawal. This study was designed to investigate the relapse rate of symptomatic …

Thirty two consecutive patients (age range 6 months-13.4 years) with severe reflux
oesophagitis were randomised to a therapeutic trial for eight weeks during which they …

Background: Lansoprazole is a new proton pump inhibitor which produces prolonged
decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard …

Ninety-eight patients with erosive and/or ulcerative esophagitis unhealed after at least 3
months' treatment with standard doses of cimetidine (≥ 1200mg daily) or ranitidine (≥ 300 …

Objective: We compared the efficacy of three different doses of the proton pump inhibitor
lansoprazole in the management of reflux esophagitis. Methods: Two hundred ninety-two …

The risk of gastric cancer after vagotomy for benign gastric and duodenal disease was
examined in a population based cohort of 7198 patients operated on during 1971-79 and …